Direkt zum Inhalt
Merck

M5353

Sigma-Aldrich

Mitomycin C

liquid, non-animal origin, suitable for cell culture, BioReagent

Synonym(e):

Ametycine, MMC, MitoExtra, Mitocin C, Mitomycin, Mitonco, Mitoplus, Mitozytrex, Mutamycin

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

UNSPSC-Code:
12352207
NACRES:
NA.76

product name

Mitomycin C ready made solution, 10 mg/mL in DMSO, ≥98% (HPLC), Cell culture tested

Qualitätsniveau

Assay

≥98% (HPLC)

Form

liquid

Lagerbedingungen

protect from light

Konzentration

10 mg/mL in DMSO

Lagertemp.

−20°C

Allgemeine Beschreibung

Mitomycin C (MMC) produced by Streptomyces caespitosus is an anticancer antibiotic agent which inhibits proliferation of various cell types in vitro. MMC is DNA alkylating agent, that causes cross linking of complementary DNA strands resulting in: mutagenesis, inhibition of DNA synthesis, initiation of DNA repair events, and activation of apoptosis. Furthermore, MMC has an effect on ribosomal RNA leading to protein synthesis inhibition.
MMC is capable of inhibiting cell proliferation of human or murine embryonic fibroblast cells at concentration range of 0.2-20μg/mL. These treated cells are subsequently used as an adherent feeder layer in long-term culture assays mainly for growth of pluripotent stem cells. Feeder layer cells support the target cells by releasing growth factors to the cell culture and detoxification of the medium. Moreover, feeder layer cells play a role in ECM proteins synthesis that controls cell culture growth. In addition, feeder layer cells are used as a substrate for attachment of the target cells.
MMC also was used for BLC (basal-like cancer) cell line.
MMC as antibiotic agent showed a potent activity against MDR gram-negative bacteria like P. aeruginosa (2 μg/mL), E.Coli (0.5μg/mL) and A. baumannii (16μg/mL). MMC also has a strong activity against gram positive bacteria (0.2μg/mL).

Technical information
1.Mitomycin C ready made solution provides a safer alternative to the powder form by preventing hazardous particles exposure.
2.Please avoid repeated freeze thaw cycles of this product.
3.Mitomycin C solutions are light sensitive and should kept in the dark.
4.It is recommended to keep Mitomycin C solutions at pH 6-7.
5.The recommended concentration of Mitomycin C in cell culture assays is 0.2-20μg/mL. (Ref.8,9,12,13) Therefore, it is recommended to dilute the ready made solution 1:500-50,000.

Vorsicht

Light sensitive

Physikalische Form

Liquid - In DMSO

Lagerklassenschlüssel

10 - Combustible liquids

WGK

WGK 2

Flammpunkt (°F)

188.6 °F - closed cup

Flammpunkt (°C)

87 °C - closed cup


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

L Ponchio et al.
Cytotherapy, 2(4), 281-286 (2002-06-04)
Mitomycin C (MMC), an antitumoral antibiotic, has been described inhibiting the proliferation of different cell types in vitro. Since irradiation is commonly used to stop the cell growth of adherent cells in several experimental models, we aimed to define the
S S Pan et al.
Molecular pharmacology, 29(6), 622-628 (1986-06-01)
After anaerobic reductive activation by either NADPH cytochrome P-450 reductase (EC 1.6.2.4) or xanthine oxidase (EC 1.2.3.2), mitomycin C readily alkylated DNA. When the mitomycin C-alkylated DNA is digested by DNase, snake venom phosphodiasterase, and alkaline phosphatase, only partial release
Ronald Domalaon et al.
Frontiers in microbiology, 10, 1556-1556 (2019-07-30)
The lack of therapeutic options to treat infections caused by multidrug-resistant (MDR) pathogens, especially Gram-negative bacteria, is apparent. Therefore, it is imperative to develop new strategies to address the problem of antimicrobial resistance. Repurposing non-antibiotic commercial drugs for antimicrobial therapy
Mitomycin, a new antibiotic from Streptomyces. I.
T HATA et al.
The Journal of antibiotics, 9(4), 141-146 (1956-07-01)
Meng Yang et al.
Nanoscale, 9(1), 334-340 (2016-12-07)
Human-induced pluripotent stem cells (iPS) possess an intrinsic tumor tropism ability. However, iPS cells are impeded in clinical applications of tumor therapy due to the formation of teratomas and their survival in normal organs such as the liver, lungs, spleen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.